EXTRAWELL PHAR (00858) announces that it is expected to achieve a mid-term profit of approximately HK$100 million to HK$105 million, turning a loss into a profit on a year-on-year basis.
Excellent Pharmaceutical (00858) announced that the group expects to achieve profitability for the six months ending September 30, 2024.
EXTRAWELL PHAR (00858) has announced that the group is expected to achieve a profit of approximately HK$100 million to HK$105 million for the six months ending on September 30, 2024, compared to a loss for the same period ending on September 30, 2023. The expected turnaround from loss to profit for this period is mainly due to non-cash items, specifically income generated from fair value changes in financial assets recognized in the income statement, as opposed to losses from fair value changes in the same non-cash items for the corresponding period in 2023.
Related Articles

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

Guosen: RWA welcomes the era of strict supervision.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

Guosen: RWA welcomes the era of strict supervision.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


